We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis

By LabMedica International staff writers
Posted on 06 Apr 2024
Print article
Image: Scientists have developed a new tool in the race to improve the diagnosis and prognosis of sepsis (Photo courtesy of Roman Zaiets/Shutterstock)
Image: Scientists have developed a new tool in the race to improve the diagnosis and prognosis of sepsis (Photo courtesy of Roman Zaiets/Shutterstock)

Sepsis, a critical condition that arises from organ dysfunction due to severe infection, can progress to severe sepsis and septic shock, leading to multi-organ failure and increased mortality rates. The complexity of diagnosing sepsis stems from the absence of a definitive test, with current detection methods depending on broad-ranged biomarkers such as CRP, PCT, and lactate levels. The disease's variability and the general approach of administering broad-spectrum antibiotics, antivirals, and antifungals underscore the urgency for more specific diagnostic and treatment strategies. New research to be presented at ECCMID 2024 highlights the success achieved by researchers in identifying distinct molecular signatures associated with the clinical signs of sepsis that could enable more accurate diagnosis and prognosis of the condition, as well as help design targeted therapies for patients who stand to benefit the most.

In this study, researchers from Lund University (Lund, Sweden) analyzed plasma samples collected over a period of five years from 1,364 adults suspected of sepsis upon their arrival at the emergency department. Of these, 913 were diagnosed with sepsis out of 1,073 who had infections. Through mass spectrometry, the researchers developed detailed molecular profiles, enabling them to identify protein patterns that accurately predict septic shock. This information was used to create a machine-learning model, categorizing patients into risk groups for developing septic shock, thus demonstrating the model's potential to predict sepsis severity and associated mortality risks accurately.

Furthermore, the researchers identified protein panels indicative of six organ dysfunctions (cardiac, CNS, coagulation, liver, kidney, respiratory) and various infections, influencing the distinct proteomic pathways influencing sepsis. Risk classifications based on organ dysfunction and infection probabilities offered insights into the mortality risks, paving the way for targeted therapeutic interventions. However, the researchers acknowledged the study's limitations, such as the need for validation across diverse cohorts and the dynamic nature of sepsis requiring continuous monitoring. This research marks a significant step toward advancing the understanding and management of sepsis, emphasizing the need for further studies to explore the progression of proteomic changes in sepsis over time.

“A fast test that provides more accurate sepsis diagnosis and could also predict who is at greater risk of poorer outcomes now seems a genuine possibility”, said co-lead author Dr. Lisa Mellhammar from Lund University. “Any research like this needs clinical validation and many hurdles must be cleared before these biomarkers are used in the clinic. But we envision this as a tool that could be deployed worldwide, as the future of early detection of sepsis.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.